Results 101 to 110 of about 410,183 (267)

Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma

open access: yesAdvanced Science, EarlyView.
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert   +8 more
wiley   +1 more source

DIXDC1 Promotes Lymphatic Metastasis and Resistance to Cuproptosis in Bladder Cancer Through Mediating DLAT

open access: yesAdvanced Science, EarlyView.
DIXDC1 drives bladder cancer progression by binding and stabilizing DLAT. This axis enhances NEK7 and CCNE2 mRNA stability to promote proliferation and lymphatic metastasis, while limiting copper‐induced DLAT oligomerization to reduce cuproptosis sensitivity, identifying DIXDC1 as a potential target linking metastasis with cuproptosis resistance ...
Hongqiong Li   +17 more
wiley   +1 more source

Comprehensive interdisciplinary treatment of an orbital lymphatic-venous malformation: a case report

open access: yesInnovative Surgical Sciences
Orbital lymphatic-venous malformations (LVMs) are rare congenital anomalies that can cause significant functional and aesthetic impairments.
Tourbier Céline   +4 more
doaj   +1 more source

PTX3 is expressed in terminal lymphatics and shapes their organization and function

open access: yesFrontiers in Immunology
IntroductionThe lymphatic system is a multifaceted regulator of tissue homeostasis and an integral part of immune responses. Previous studies had shown that subsets of lymphatic endothelial cells (LEC) express PTX3, an essential component of humoral ...
Andrea Doni   +18 more
doaj   +1 more source

Abnormal Lymphatic Sphingosine-1-Phosphate Signaling Aggravates Lymphatic Dysfunction and Tissue Inflammation [PDF]

open access: bronze, 2023
Dongeon Kim   +17 more
openalex   +1 more source

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

open access: yesAdvanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang   +21 more
wiley   +1 more source

Amphibians: circulation: lymphatic hearts

open access: yes, 2016
Presents lymphatic hearts of amphibians at working and elucidate its function and anatomical relationsComponente Curricular::Educação Superior::Ciências Biológicas::Biologia GeralComponente Curricular::Educação Superior::Ciências Agrárias::Medicina ...
Sebben, Antonio
core   +1 more source

AHR‐Responsive Carbon Dots Orchestrate Skin Wound Healing and Colonic Mucosal Repair via Treg‐Mediated Macrophage Efferocytosis

open access: yesAdvanced Science, EarlyView.
Guided by pharmacophore modeling and molecular docking, aryl hydrocarbon receptor (AHR)‐responsive carbon dots were synthesized. They bind directly to AHR and expand gut‐resident regulatory T (Treg) cells. Treg‐derived C‐C motif chemokine ligand 1 (CCL1) enhances macrophage efferocytosis, creating a pro‐regenetative niche that promotes colonic mucosal ...
Zilu Zhu   +6 more
wiley   +1 more source

Dual‐Target Nectin‐4/FAP Heterobivalent Probe 68Ga/177Lu‐FZ‐NF‐1 for Triple‐Negative Breast Cancer: Preclinical Theranostic Evaluation and First‐in‐Human Translation

open access: yesAdvanced Science, EarlyView.
A novel hetero‐bivalent agent, 68Ga/177Lu‐FZ‐NF‐1, concurrently targets Nectin‐4 and FAP in triple‐negative breast cancer. It yields significant preclinical tumor regression and clinically identifies additional metastatic lesions missed by 18F‐FDG PET, demonstrating promising theranostic potential for personalized management.
Ye Li   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy